Insights - It appears that Vertex Pharmaceutical’s (VRTX) decision to scale back its support for its Hepatitis-C treatment, Incivek, was well reasoned in the face of continued … Continue Reading
PremiumLong Ideas - Since our July 24 report on Enanta Pharmaceuticals (ENTA), shares of the HCV company have risen over 15%, even after accounting for the sell-off in … Continue Reading
Read nowLong Ideas - Since making their market debut in March, shares of Enanta Pharmaceuticals (ENTA) have remained virtually flat, excluding a post-IPO pop (shares closed at $17.18 on … Continue Reading
Read nowInsights - Achillion Pharmaceuticals (ACHN) has been all over the news in the last week (and up more than 100%), the latest target of takeover fever in … Continue Reading
Read nowRecap - It looked briefly at mid-week like the biotech sector’s correction might be a comical 48-hour event, but investors are in a tizzy over the emerging … Continue Reading
Read nowInsights - It’s New Year’s Eve. This year flew past – and so did biotech. The NASDAQ Biotechnology Index (NBI) will end the year up 60%, while … Continue Reading
Read nowInsights - PropThink readers who followed us into Enanta Pharmaceuticals (ENTA) in July saw their money double through this week. AbbVie (ABBV), which uses an Enanta-developed hepatitis drug (the protease … Continue Reading
Read now
